摘要
目的探究维奈克拉(VEN)联合用药对老年急性髓系白血病(AML)患者的治疗效果。方法回顾性选取2020年1月至2023年3月濮阳市安阳地区医院收治的老年AML患者82例为研究对象,患者均接受VEN联合去甲基化药物(HMAs)用药治疗,分析患者的治疗反应性。结果研究中初治患者占比较高,有51例,另31例为经治患者,初治患者中33例(64.71%)患者接受VEN联合阿扎胞苷治疗,其余18例(35.29%)患者接受VEN联合地西他滨治疗,而经治组中25例(80.65%)接受VEN联合阿扎胞苷治疗,其余6例(19.35%)患者接受VEN联合地西他滨治疗。完全缓解患者共39例,占比47.56%,不完全缓解患者19例,占比23.17%,部分缓解患者5例,占比6.10%,总体反应率为76.83%,微小残留病阴性率为37.80%。患者随访时间为2~40个月,中位随访时间19个月,截至2023年4月30日,82例患者中62例(75.61%)存活,8例(9.76%)死亡,另有2例(2.44%)患者失访。患者≥3级不良反应发生率为87.80%,其中初治患者发生率为94.12%(48/51),经治患者发生率为96.77%(30/31)。结论接受VEN联合用药治疗的老年AML患者能取得较好的临床疗效,但其不良反应发生率高。
Objective To explore the efficacy of venetoclax(VEN)combination therapy in elderly patients with acute myeloid leukemia(AML).Methods Eighty-two elderly AML patients admitted to Puyang City Anyang District Hospital from January 2020 to March 2023 were retrospectively selected.All patients were treated with VEN in combination with hypomethylating agents(HMAs).The treatment response in patients was analyzed.Results Among the selected patients,there were 51 therapy-naive patients and 31 re-treated patients.Of the therapy-naive patients,64.71%(33/51)received VEN in combination with azacitidine and the remaining 35.29%(18/51)were treated with VEN in combination with decitabine.Of the re-treated patients,25(80.65%)received VEN in combination with azacitidine and the remaining 6(19.35%)patients were treated with decitabine.There were 39 complete response patients,accounting for 47.56%,19 incomplete response patients,accounting for 23.17%,5 partial response patients,accounting for 6.10%.The overall response rate was 76.83%,and the negative rate of minimal residual disease was 37.80%.The patient was followed up for 2-40 months,with a median follow-up time of 19 months.As of April 30,2023,out of 82 patients,62(75.61%)survived,8(9.76%)died,and 2(2.44%)patients were lost to follow-up.The total incidence of grade 3 or greater adverse reactions was 87.80%,including 94.12%(48/51)in therapy-naive patients and 96.77%(30/31)in re-treated patients.Conclusion The VEN combination therapy achieves good treatment response in elderly AML patients,while it is associated with a high incidence of adverse effects.
作者
唐广
武永强
张晓南
陈杰甫
孟君霞
TANG Guang;WU Yongqiang;ZHANG Xiaonan;CHEN Jiefu;MENG Junxia(Department of Hematology,Puyang City Anyang District Hospital,Puyang 455000,China)
出处
《河南医学研究》
CAS
2024年第9期1674-1678,共5页
Henan Medical Research
